Immatics (NASDAQ:IMTX) Stock, Quote.Headers.trade-ideas

Immatics

Immatics NV is a biotechnology company that is engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies.

Genetic,Research,And,Biotech,Science,Concept.,Human,Biology,And,Pharmaceutical

Biotech

Equities

News

Health Care

Financing

Offerings

Movers

Trading Ideas

General

IMTX

Immatics announced updated Phase 1b data for its IMA203 therapy in metastatic melanoma. A deep tumor reduction response was observed in about half of the patients, with positive survival benefits shown. Phase 3 trials are set to begin by December 2024.

Why Is Cancer-Focused Immatics Stock Trading Lower On Thursday?

Earnings

Earnings Beats

Large Cap

Small Cap

Management

Markets

Analyst Ratings

TRDA

AstraZeneca (NASDAQ: AZN) announced that the combination therapy of its PD-L1 inhibitor, Imfinzi (durvalumab), and PARP inhibitor, Lynparza (olaparib), has been approved in the EU to treat certain patients with primary advanced or recurrent endometrial cancer, also known as uterine cancer.

AstraZeneca Imfinzi Combo Gets EU Nod for Uterine Cancer

Earnings Misses

HALO

UTHR

United Therapeutics‘ (NASDAQ: UTHR) second-quarter 2024 earnings of $5.85 per share missed the Zacks Consensus Estimate of $6.33. Earnings rose 12% year over year on the back of higher product sales.

United Therapeutics Q2 Earnings Lag, Sales Top Estimates

Immatics NV

Pure Storage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSTG#NYSE">PSTG</a>) reported its Q3 earnings results on Tuesday, December 3, 2024 at 04:05 PM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
Pure Storage beat estimated earnings by 19.0%, reporting an EPS of $0.5 versus an estimate of $0.42.
Revenue was up $68.23 million from the same period last year.
<h3>Historical Earnings Summary</h3>
During the previous quarter, the company beat on EPS by $0.07, leading to a 16.0% drop share price change the next day.
Here's a look at Pure Storage's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2025</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.37</td>
<td>0.21</td>
<td>0.44</td>
<td>0.4</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.44</td>
<td>0.32</td>
<td>0.50</td>
<td>0.5</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>755.06M</td>
<td>680.97M</td>
<td>782.31M</td>
<td>763.36M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>763.77M</td>
<td>693.48M</td>
<td>789.80M</td>
<td>762.84M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Pure Storage <a href="https://www.benzinga.com/quote/PSTG/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

PSTG

Earnings Breakdown: Pure Storage Q3

Box (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BOX#NYSE">BOX</a>) reported its Q3 earnings results on Tuesday, December 3, 2024 at 04:05 PM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
Box beat estimated earnings by 7.000000000000001%, reporting an EPS of $0.45 versus an estimate of $0.42.
Revenue was up $14.38 million from the same period last year.
<h3>Overview of Past Earnings</h3>
In the previous quarter, the company beat on EPS by $0.04, resulting in a 11.0% increase change in the share price the following day.
Here's a look at Box's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2025</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.40</td>
<td>0.36</td>
<td>0.38</td>
<td>0.38</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.44</td>
<td>0.39</td>
<td>0.42</td>
<td>0.36</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>269.18M</td>
<td>262.04M</td>
<td>262.97M</td>
<td>263.69M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>270.04M</td>
<td>264.66M</td>
<td>262.88M</td>
<td>261.54M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Box <a href="https://www.benzinga.com/quote/BOX/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Box: Q3 Earnings Insights

The Company's common stock will begin trading on a split-adjusted basis when the market opens on December 6, 2024, under its current trading symbol "ENSC". The new CUSIP number of the Company's common stock following the reverse stock split will be 293602 504.
The reverse stock split is intended, among other things, primarily to increase the bid price of the Company's common stock to enable the Company to regain compliance with the minimum bid price requirement of $1.00 per share for continued listing on The Nasdaq Capital Market.
 &nbsp;

Stock Split

ENSC

Ensysce Biosciences Plans To Implement 1-For-15 Reverse Split Of Its Common Stock, Effective December 6, 2024

Qurate Retail, Inc. ("Qurate Retail" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QRTEA#NASDAQ">QRTEA</a>, QRTEB, QRTEP))) announced that it received approval from the Listing Qualifications Department of the Nasdaq Stock Market ("Nasdaq") to transfer the listing of the Company's Series A common stock ("QRTEA"), Series B common stock, and 8.0% Series A Cumulative Redeemable Preferred Stock (collectively, the "Securities") from the Nasdaq Global Select Market to the Nasdaq Capital Market. The listing of the Company's Securities was transferred to the Nasdaq Capital Market at the opening of business on December 2, 2024. This follows the notice received from Nasdaq on June 10, 2024 that, based on the closing bid price for QRTEA for 30 consecutive business days, Qurate Retail no longer complied with the minimum bid price requirement for continued listing on the Nasdaq Global Select Market (the "Minimum Bid Price Requirement").

QRTEA

Qurate Retail Transfers Equity Listing To The Nasdaq Capital Market

Dividends

TXNM

TXNM Energy Increases Annual Dividend From $1.55 to $1.63

WIIM

Campbell Soup shares are trading lower after the company reported Q1 sales that missed analyst estimates, despite better-than-expected adjusted EPS. Additionally, the company announced Mick Beekhuizen will succeed Mark Clouse as CEO, effective February 1, 2025.

<a href="http://www.xpo.com/">XPO</a>&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPO#NYSE">XPO</a>),&nbsp;a leading provider of freight transportation in North America,&nbsp;today reported certain preliminary LTL segment operating metrics for November 2024. LTL tonnage per day decreased 4.0%, as compared with November 2023, attributable to a year-over-year decrease of 4.2% in shipments per day and an increase of 0.2% in weight per shipment. Actual results for November 2024 may vary from the preliminary results reported above.

XPO Provides North American LTL Operating Data For November 2024; LTL Tonnage Per Day Decreased 4.0%, As Compared With November 2023, Attributable To A YoY Decrease Of 4.2% In Shipments Per Day And An Increase Of 0.2% In Weight Per Shipment

CURV

Torrid Holdings shares are trading lower after the company reported worse-then-expected Q3 financial results and issued Q4 and FY24 revenue guidance below estimates.

Featuring Analytics-Driven Augmented Viewing Experience Starting Dec. 10

GENI

TNT Sports Partners With NBA 2K And Genius Sports To Launch NBA 2K25 DataCast Telecast On truTV And Max For 2024 Emirates NBA Cup Knockout Round

Meta Platforms Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) Global Affairs President Nick Clegg flagged the company&#8217;s evolving role in content moderation amid global elections, the latest of which was the <a target="_blank" href="https://about.fb.com/news/2024/12/2024-global-elections-meta-platforms/" rel="noreferrer noopener">U.S. presidential election</a>.
Clegg acknowledged the company&#8217;s responsibility as an operator of platforms where public exchange of views occurs amid elections in the world&#8217;s biggest democracies, including India, Indonesia, Mexico, and the European Union.&nbsp;&nbsp;
Previously, social media companies drew flak globally for spreading misinformation and content that perpetrated violence during elections.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/12/42295863/apple-might-have-to-commit-1-billion-to-indonesia-to-reverse-iphone-16-ban" rel="noreferrer noopener">Apple Might Have To Commit $1 Billion To Indonesia To Reverse iPhone 16 Ban</a>
Facebook had suspended Donald Trump&#8217;s (then U.S. President) account from January 6, 2021, to January 7, 2023, following the Capitol Hill riot <a target="_blank" href="https://www.benzinga.com/news/21/06/21433780/facebook-suspends-trumps-accounts-for-2-years-former-president-calls-it-an-insult" rel="noreferrer noopener">in January 2021</a>. X, formerly&nbsp;known as Twitter, also banned Trump&#8217;s account after Facebook.
Therefore, Clegg acknowledged that the company had evolved its approach to elections since 2016 via trial and error, including forming a team of experts from its intelligence, data science, content and public policy, and legal teams.
In 2024, Meta ran multiple election operations centers globally amid primary elections, including the U.S., Bangladesh, Indonesia, India, Pakistan, and the EU Parliament.
Meta updated and applied its content policies throughout the year to help users freely communicate and exchange views.
Meta introduced political content controls on Facebook, Instagram, and Threads in the U.S. to recommend political content based on users&#8217; choices, the blog read. It is amid efforts to roll out the feature globally.&nbsp;
Meta permitted social media users to question or flag doubts about election processes, avoiding election-related speculation or bias that could promote violence.
For paid content, Meta&nbsp;barred&nbsp;ads that questioned the legitimacy of an election, something the company had done since 2020.
Meta revised its&nbsp;penalties system&nbsp;in 2023 to enable an effective exchange of views while punishing the policy violators. The company conducted annual audits of words it considered slurs under its Hate Speech policy.
Meta also&nbsp;revised its penalty protocol for public figures suspended for violations.
Clegg also acknowledged monitoring deepfakes and AI-enabled disinformation campaigns during the elections that helped combat potential threats from the misuse of generative AI.
Meanwhile, Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) chief and owner of X, Elon Musk, has actively promoted free speech and Trump during his <a target="_blank" href="https://www.benzinga.com/news/24/10/41353213/tesla-ceo-elon-musk-to-campaign-for-trump-in-pennsylvania-asks-attendees-to-support-free-speech-ther" rel="noreferrer noopener">2024 presidential campaigns</a>.
Meanwhile, Trump now expresses his views on Trump Media &amp; Technology Group Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>) Truth Social, where he has <a target="_blank" href="https://www.benzinga.com/markets/cryptocurrency/24/10/41333815/whats-going-on-with-trump-media-technology-group-stock-on-tuesday" rel="noreferrer noopener">a majority stake</a>.
Price Action: META stock closed higher by 3.61% at $613.65 on Tuesday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/24/12/42292183/citi-trends-q3-earnings-tops-estimates-margin-expansion-revises-guidance" target="_blank" rel="noreferrer noopener">Citi Trends Sales Beat Estimates With Margin Gains Despite Q3 Loss</a></li>
</ul>
Photo via Shutterstock

Tech

TSLA

Meta Platforms Talks Political Misinformation, Content Moderation In Latest Blog

Topline results demonstrated a statistically significant lower "Drug Liking" for the clinical doses of oral nalbuphine (81mg and 162mg) compared to 6mg IV butorphanol. The supratherapeutic dose of oral nalbuphine (486mg) was numerically lower than the 6mg IV butorphanol for "Drug Liking" but the results were not statistically significant.
Secondary endpoints included&nbsp;pharmacodynamic markers and patient reported outcomes, which were generally consistent with the primary endpoint. No serious adverse events were reported in the study.

TRVI

Trevi Therapeutics Reports Results From  Human Abuse Potential Study Of Oral Nalbuphine; Statistically Significant Lower 'Drug Liking' For 81Mg And 162Mg Doses Of Oral Nalbuphine Vs. Butorphanol Covering Clinical Dose Range

NeuroPace, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NPCE#NASDAQ">NPCE</a>), a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced completion of enrollment and implant procedures in its feasibility investigational device exemption (IDE) study of the RNS&#xAE; System for the treatment of Lennox-Gastaut Syndrome (LGS), a devastating form of childhood-onset epilepsy characterized by cognitive dysfunction and frequent generalized onset seizures that often lead to injury.
The IDE study uses the RNS System, which has demonstrated safety and effectiveness of brain-responsive stimulation for treating medically intractable focal onset seizures in people 18 and older, to evaluate whether brain-responsive neurostimulation can also be used to treat LGS.
NeuroPace received a $9.3 million National Institutes of Health (NIH) grant through the Brain Research through Advancing Innovative Neurotechnologies&#xAE; <a href="https://www.globenewswire.com/Tracker?data=w3qN0nEC75XJaIt7q6KRHCZ4H0uag9XxaWKGEZo6HH8AOctWZP3KjH72ghrvCHhLQq6ttLKNmiA1Eqc05sriPJRCNAJr-R38uNjkfeTyNMI=">(BRAIN) Initiative</a> to evaluate its responsive neuromodulation technology in those who suffer from LGS. The IDE study funded by the grant was conducted at six sites and enrolled a total of 20 patients 12 years of age and older with LGS and drug-resistant generalized onset seizures. The study will evaluate the safety and effectiveness of the RNS System in treating seizures associated with LGS.

Contracts

NPCE

NeuroPace Completes Enrollment In Feasibility Study Of RNS System For Lennox-Gastaut Syndrome;  Received A $9.3M National Institutes Of Health Grant Through The Brain Research Through Advancing Innovative Neurotechnologies Initiative To Evaluate Its Responsive Neuromodulation Technology In Those Who Suffer From LGS

Torrid Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CURV#NYSE">CURV</a>) reported its Q3 earnings results on Tuesday, December 3, 2024 at 04:05 PM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
Torrid Holdings missed estimated earnings by -133.0%, reporting an EPS of $-0.01 versus an estimate of $0.03.
Revenue was down $11.64 million from the same period last year.
<h3>Historical Earnings Summary</h3>
During the previous quarter, the company missed on EPS by $0.0, leading to a 6.0% drop share price change the next day.
Here's a look at Torrid Holdings's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.08</td>
<td>0.07</td>
<td>-0.08</td>
<td>-0.05</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.08</td>
<td>0.12</td>
<td>-0.04</td>
<td>-0.03</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>285.37M</td>
<td>282.40M</td>
<td>274.83M</td>
<td>245.83M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>284.64M</td>
<td>279.77M</td>
<td>293.54M</td>
<td>275.41M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Torrid Holdings <a href="https://www.benzinga.com/quote/CURV/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Torrid Holdings Earnings Analysis: Q3 Recap

Guidance

Torrid Holdings Sees Q4 Revenue $255M-$270M Vs $290.63M Est.

IREN Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IREN#NASDAQ">IREN</a>) (ACN 629 842 799) ("IREN") today announced its intention to offer, subject to market and other conditions, $300&nbsp;million aggregate principal amount of convertible senior notes due 2030 (the "notes") in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). IREN also expects to grant the initial purchasers of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date the notes are first issued, up to an additional $45&nbsp;million principal amount of notes.
The notes will be senior, unsecured obligations of IREN, will accrue interest payable semi-annually in arrears and will mature on June 15, 2030, unless earlier repurchased, redeemed or converted. Noteholders will have the right to convert their notes in certain circumstances and during specified periods. IREN will settle conversions by paying or delivering, as the case may be, cash, its ordinary shares or a combination of cash and its ordinary shares, at its election.

IREN

IREN Announces Its Intention To Offer $300M Aggregate Principal Amount Of Convertible Senior Notes Due 2030

BASE

Couchbase shares are trading lower after the company issued Q4 revenue guidance below estimates.

Insider Trades

Goldman Sachs CEO David Solomon Sells 6,550 Shares For ~$4M At $610.91 Each, Retains 117,883 Shares Directly And 16,171 Indirectly Through Family Trust

Salesforce shares are trading higher after the company reported Q3 earnings and raised its guidance.

<a href="https://www.globenewswire.com/Tracker?data=8Tf7Z3_YTnk-drIFCyK3YwK5fBKtJERg8a5F3K8syiG68jnjCZnBJKIYCATZd01jimcmqpP1528lJYHqXWY-ma414azilZr-CI5Zg79wOZw=">Tectonic Therapeutic, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TECX#NASDAQ">TECX</a>) ("Tectonic") a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors ("GPCRs"), today announced it will host a virtual key opinion leader (KOL) event on Thursday, December 12, 2024 from 4:00 PM to 6:00 PM ET. To register, <a href="https://www.globenewswire.com/Tracker?data=0eWtnXxZi0DLMosegLjoiOoxfutWhH7qSlf7dqC2xfyHNQu-tfX-H-3N7YMQ4Mml7pdz18Wt2RW-5K2mAnTcbFd--zxV1VGeBPo_CnnN2LU=">click here</a>.
Key opinion leaders will include John R. Teerlink, MD, FHFSA (University of California San Francisco) and Raymond L. Benza, MD, FACC, FAHA, FACP (Icahn School of Medicine at Mount Sinai), who will discuss the unmet medical need and current treatment landscape for patients with Group 2 Pulmonary Hypertension due to Heart Failure with Preserved Ejection Fraction (Group 2 PH-HFpEF).
The event will focus on Tectonic's lead program, TX45, an investigational Fc-relaxin fusion protein with optimized pharmacokinetics and biophysical properties that activates the RXFP1 receptor, the GPCR target of the hormone relaxin. TX45 is being evaluated in patients with Group 2 PH-HFpEF in an ongoing Phase 1b hemodynamic proof-of-concept study and a Phase 2 clinical proof-of-concept study.
A live question and answer session will follow the formal presentations.

TECX

Tectonic Therapeutic To Host KOL Event On The Unmet Need In Group 2 PH-HFpEF And TX45 As A Potential Treatment On Thursday, December 12, 2024 From 4:00 PM To 6:00 PM ET

The partnership also includes the successful demonstration of Parsons' software-defined satellite communications solution using Globalstar's Low Earth Orbit (LEO) satellite constellation.

GSAT

Parsons, Globalstar Enter Exclusive Partnership To Support The Public, Government, And Defense Sectors

Immatics GAAP EPS of -€0.11, revenue of €50.56M

Immatics (IMTX) is providing the first clinical data update from the ongoing Phase 1 dose escalation trial evaluating its next-generation, half-lif...

Immatics announces clinical data on TCER IMA402 targeting PRAME

Immatics (IMTX) has released an update. Immatics reported a significant increase in collaboration revenue for the nine months ending September 30, ...

Immatics Sees Revenue Surge Despite R&D Expenses

Cash and cash equivalents as well as other financial assets total $549.2M as of September 30, 2024, compared to $476.8M as of December 31, 2023. Th...

Immatics sees cash runway into 2H27

Leerink lowered the firm's price target on Immatics (IMTX) to $18 from $19 and keeps an Outperform rating on the shares. Concurrent with Q4 earning...

Immatics price target lowered to $18 from $19 at Leerink

BofA lowered the firm's price target on Immatics (IMTX) to $15 from $16 and keeps a Buy rating on the shares following Q3 earnings, which included ...

Immatics price target lowered to $15 from $16 at BofA

In a report released yesterday, Kelly Shi from Jefferies assigned a Buy rating to Immatics (IMTX – Research Report), with a price target of $20.00....

Jefferies Releases a Buy Rating on Immatics (IMTX)

In a report released on November 22, Graig Suvannavejh from Mizuho Securities maintained a Buy rating on Immatics (IMTX – Research Report), with a ...

Immatics: Promising Pipeline and Financial Health Justify Buy Rating

Goldman Sachs analyst Rajan Sharma introduced a Buy rating and $13.50 price target for Immatics (IMTX) after previously being Not Rated on the earl...

Immatics moved to Buy from Not Rated at Goldman Sachs

Immatics N.V. ( ($IMTX) ) has released its Q3 earnings. Here is a breakdown of the information Immatics N.V. presented to its investors. Immatics N...

Immatics N.V. Reports Strong Q3 2024 Progress and Financials

Press Releases

Immatics Appoints Alise Reicin to Board of Directors

Immatics Announces Second Quarter 2024 Financial Results and Business Update

Immatics Announces Upcoming Oral Presentation at the Society for Melanoma Research Congress 2024

Immatics Presents Clinical Proof-of-Concept Data from Ongoing Phase 1 Dose Escalation Trial with TCR Bispecific Molecule TCER® IMA401 Targeting MAGEA4/8 at ESMO 2024 and Provides Development Update

Immatics Announces Upcoming Oral and Poster Presentations at the Society for Immunotherapy of Cancer Annual Meeting 2024

Immatics Announces Updated Phase 1b Clinical Data on ACTengine® IMA203 TCR-T Targeting PRAME in Melanoma Patients and Provides Update on Upcoming SUPRAME Phase 3 Trial

Immatics Announces Proposed $150 Million Public Offering

Immatics Announces Pricing of $150 Million Public Offering

Immatics Announces Multiple Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on TCR-T Therapy Candidates Targeting PRAME

Comments

Immatics

Immatics (IMTX) Forecast

Immatics (NASDAQ:IMTX) Stock, Quote.Headers.trade-ideas

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga